1. Biorchestra procures 20 billion KRW investment

As a biotech start-up with the technology to develop new RNA-based medications, Biorchestra is working on the development of BMD-001, a treatment for Alzheimer’s disease, using microRNA interference technology. On the 21st of this month, the company successfully attracted investments of 20 billion KRW through Series B for the development of treatments for degenerative neurological disorders including Alzheimer’s. Jinhyeob Ryu, the CEO of Biorchestra, stated "Many companies have suffered from difficulties in developing treatments due to serious adverse effects related to their drugs, such as inflammation and brain swelling. We intend to develop a new medicine for Alzheimer’s with a more fundamental solution that will overcome the limitations of side effects and tackle the cause of the disease."

2. E&S Healthcare attracts 9 billion KRW in investments

E&S Healthcare succeeded in gathering investments totaling 9 billion KRW. As a pioneer developer of blood-based breast cancer diagnosis kits, the company aims to become a global diagnosis company. Those who have invested in the company include NHN, Mirae Asset, Daewoo, Magellan, BHA Investment Cooperative, E&SL, Intervalue Partners and Daedeok Venture Partners. The invested funds are expected to be used in preparation for clinical entry in the domestic market and entry into the US market; full-fledged commercialization in Europe; expansion of the company’s own pipelines and organizational expansion. Gyeonghun Seo, CEO of E&S Healthcare, reported, "Support from relevant organizations such as the Bio Healthcare Association has been of great help." He continued "Using these investments, we plan to reinforce our organization and pipelines, focus on marketing activities at home and abroad, and accelerate the penetration into the global market."

3. G2GBIO signs joint R&D agreement (CNU Hospital)
 

On July 25, at the Biomedical Convergence Research Center, the Biomedical Research Institute of Chungnam National University (CNU) Hospital signed a business agreement for joint R&D with G2GBIO, a company which has received attention recently in connection with its platform technology for the development of sustained-release(SR) medicines. Minho Song, the president of CNU Hospital, explained, "Joint R&D with a company equipped with commercialization capacities is very much needed to put R&D results based on ideas in the field into practical use. We will provide full support to achieve commercialization by creating an ecosystem conducive for joint R&D activities among academia, industry, hospitals and facilitating firms to make it easier to engage in clinical trials." 

D. Tomocube able to distinguish 19 species of germs in 0.3 seconds using AI-embedded hologram technology
 

Eyes are on Tomocube, which has integrated AI technology into a microscope. Since last year, the company has continued systematic upgrades by forming a team of six experts specializing in AI technology. The AI-based microscope is able to distinguish normal cells from cancer cells based on their color and to delete some flaws (noise) in the microscopic images. Such a process uses AI technology based on learning data. The utilization of this technology is expected to greatly reduce the time required for analysis. The chemical analysis process currently in use takes about a day after the blood is extracted, but the AI-based microscope requires only 0.3 seconds. This suggests a new solution to the previous treatment approach under which medication is administered to kill bacteria due to a long processing time. Hyeonseok Min, Tomocube’s AI Team Leader, said that "In addition to the technology to identify the cells, we are adding various other technologies such as object classification, tracking and changeover. We will carry on research that can contribute the creation of beneficial AI models in many places based on the meaningful medical data secured."
저작권자 © 헬로디디 무단전재 및 재배포 금지